Company / Operating Cash Flow
Veracyte, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$136.3M
FY2025
5-year range
-$31.6M / $136.3M
FY2021-FY2025
Trend
+81.5%
vs FY2024
Sector context
#93 of 158
Health Care
What the data says
At $136M, Veracyte, Inc.'s operating cash flow ranks #93 of 158 in the Health Care sector. Operating Cash Flow has increased for 4 consecutive years, from -$32M in FY2021 to $136M in FY2025.
Based on SEC 10-K filings.
$136M in FY2025 with a 3-year CAGR of +162.5%.
Improved from $44M to $136M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +162.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#93 of 158 in Health CareTop 59% of 158This company $136.3M Sector average $1.0B
▼
-86.8% below sector average
Key checks
Key Insights
- Veracyte, Inc.'s operating cash flow has grown for 4 consecutive years.
- 3-year CAGR of +162.5%, indicating consistent growth.
- In FY2025, operating cash flow increased 81.5% year-over-year.
- Ranks #93 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $136.3M | +81.5% |
| FY2024 | $75.1M | +69.8% |
| FY2023 | $44.2M | +486.9% |
| FY2022 | $7.5M | +123.8% |
| FY2021 | -$31.6M | -225.6% |
| FY2020 | -$9.7M | -200.5% |
| FY2019 | -$3.2M | +76.1% |
| FY2018 | -$13.5M | +43.5% |
| FY2017 | -$23.9M | +14.5% |
| FY2016 | -$28.0M | -3.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026